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Small laboratory animals are powerful models for investigating in vivo viral
pathogenesis of a number of viruses. For adenoviruses (AdVs), however, spe-
cies-specificity poses limitations to studying human adenoviruses (HAdVs) in
mice and other small laboratory animals. Thus, this review covers work on
naturally occurring mouse AdVs, primarily mouse adenovirus type 1 (MAdV-
1), a member of the species Murine mastadenovirus A. Molecular genetics,
virus life cycle, cell and tissue tropism, interactions with the host immune
response, persistence, and host genetics of susceptibility are described. A brief
discussion of MAdV-2 (member of species Murine mastadenovirus B) and
MAdV-3 (member of species Murine mastadenovirus C) is included. We
report the use of MAdVs in the development of vectors and vaccines.
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Study of animal adenoviruses is of importance both
because of the fundamental knowledge gained from
comparative biology with human adenoviruses
(HAdVs) and because of the ability to study the patho-
genesis of an adenovirus (AdV) in its natural host using
experimental infections, which is not possible for
HAdVs. Moreover, AdV species-specificity limits the
use of small animal models for the study of human
AdV pathogenesis. The ease and relative low cost of
studying mice in the laboratory is augmented by the
wealth of genetically distinct inbred strains of Mus mus-
culus and the ability to make transgenic mice to test the
functional importance of mouse genes for virus infec-
tion. These are coupled with a rich supply of immuno-
logical reagents for studying the mouse host response.
Mouse adenovirus MAdV-1 (Ad-FL) [1] was among
the first nonprimate adenoviruses identified in the
1950s and 1960s, along with canine hepatitis virus,
CAdV-1 [2], fowl AdV-1 (CELO)[3], and bovine AdV
[4]. MAdV-1 has a tropism for endothelial cells and
cells of the monocyte/macrophage lineage, and it also
infects astrocytes [5–7]. MAdV-1 infects tissues
throughout the mouse, and the highest levels of virus
are found in the brain, spinal cord, and spleen after
intraperitoneal infection [5,6,8]. MAdV-1 causes
encephalitis in susceptible mice [6,8,9], myocarditis
[10–12], and respiratory infection [13,14]. A second
mouse AdV, MAdV-2 (K87), was isolated from feces
of laboratory mice in Japan in 1966 [15]. Both in cul-
tured cells and in mice, MAdV-2 has a tropism for
cells of the intestinal tract, but it does not cause
apparent disease in mice [15–17]. MAdV-1 and -2 were
isolated from laboratory mice, whereas a third type of
mouse AdV, MAdV-3, was isolated from a liver from
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a striped field mouse, Apodemus agrarius [18]. MAdV-3
has a primary tropism for cardiac tissue, and it is pre-
sent at high levels in myocardium, not in the brain,
and at lower levels in most other organs [18]. MAdV-3
is genetically more similar to MAdV-1 than to
MAdV-2.
The MAdV types discovered to date seem to have
low significance as natural pathogens, and only a lim-
ited number of prevalence studies in the wild [19–21]
and in commercial or research colonies [22–26] have
been performed. These studies indicate a moderate
serologic prevalence of MAdV-2 with considerable
site-to-site variability. More recently, virome profiling
studies have added more insights and provided evi-
dence for new rodent adenoviruses [27–29]. The ‘mur-
ine’ adenoviruses that have been characterized to date
do not infect infant rats [30], and thus this review
covers only mouse adenoviruses.
MAdVs have similarities and differences compared
to HAdVs that will be discussed below. We include
comparisons of molecular genetics and gene expres-
sion, cell and tissue tropism, and viral persistence. The
MAdV-mouse host system enables studies of viral
pathogenesis that have no direct comparison to HAdV
studies. We also discuss the use of MAdVs for vacci-
nes and gene delivery vectors. Readers are also direc-
ted to previous reviews of mouse adenoviruses [31,32]
for additional historical perspectives and further
details.
Mouse adenovirus type 1
Isolation, physical, and molecular genetic
properties
MAdV-1 was isolated by Hartley and Rowe when
they were establishing Friend mouse leukemia virus
in culture, and they subsequently isolated it from
Swiss mice in a mouse colony, designating it ‘M.Ad.
virus strain FL’ [1]. The virus has physical and sero-
logic properties like HAdVs [1,31], and infected mice
transmit the virus to uninoculated cage contacts, but
there is no apparent transmission through the air or
via bedding from cages of infected mice [1,33].
MAdV-1 has subsequently been studied in cell culture
and mice. One isolate of MAdV-1 is in the American
Type Culture Collection (Cat. no. VR550), deposited
by Steven Larsen; we and others from 1981 onward
have used an isolate obtained directly from Dr. Lar-
sen, referred to as ‘standard’. These two isolates have
minor molecular and pathogenetic differences [34],
and it is not known which strain (if either) was used
prior to 1981.
MAdV-1 has a 30 944 bp double-stranded genome
with 93 nt inverted terminal repeats [34–36]. The com-
plete sequence is available as NC_000942.1 [37].
Another entry with in silico-derived annotations of the
same sequence is AC_000012.1 [38]; it has some pre-
dicted genes not in agreement with published experi-
mental evidence (e.g., in silico E1A annotation does
not match transcription mapping and cDNA sequenc-
ing data) [31].
In broad terms, the genome structure of MAdV-1 is
similar to that of HAdV-5. It encodes genes with
sequence and functional similarity to HAdV early (E)
regions 1–4, a major late promoter (MLP) with a tri-
partite leader, and late (L) genes encoding the major
virion proteins and proteins involved in morphogenesis
[reviewed in Ref. [31]]. The gene arrangement is like
that of HAdVs. A terminal protein is associated with
the 50 end of each end of the genome [36]. In fine
details, there are some differences between HAdVs and
MAdV-1 in gene expression and function. For exam-
ple, MAdV-1 does not encode virus-associated RNA
(VA RNA) [37], which in HAdV infections counteracts
the host protein kinase R (PKR) antiviral response
[39].
Instead of two major isoforms of the E1A protein
found in HAdV-5, MAdV-1 only has one 200 aa pro-
tein, corresponding to the larger (289 aa, ‘13S’)
HAdV-5 protein [40]. Although its overall sequence
similarity to HAdV E1A proteins is low, it has about
40% similarity to conserved regions 1 (CR1), CR2,
and CR3. MAdV-1 E1A has functional similarity to
HAdV E1A; it interacts with cellular proteins pRb and
p107 via its CR2 domain and is involved in the regula-
tion of cell proliferation of quiescent cells [41]. MAdV-
1 E1A, like HAdV E1A, interacts with a component
of the mediator transcriptional complex, Sur2, now
known as Med23, through the E1A CR3 domain [42].
This finding enabled the demonstration that Med23 is
required for efficient replication of adenoviruses, which
was unable to be tested directly using HAdVs.
Transcription mapping has not been done for
MAdV-1 E2, but the predicted proteins have good
sequence similarity with the three HAdV E2 proteins,
which are involved in viral DNA synthesis. The DNA
polymerase, DNA binding protein, and pTP, which is
involved in protein priming of DNA synthesis, have
33–57% sequence similarity to HAdV proteins [37,43].
MAdV-1 E3 is distinct from the E3 regions of
HAdVs. There are three mRNAs encoded that share
50 and 30 termini but differ in splicing of the third
exon, such that the three predicted proteins share
amino terminal sequences but have different carboxy-
terminal domains [44]. Only one of the MAdV-1 E3
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proteins is detected in wild-type virus-infected cells,
the E3 gp11K protein [45]. As is true of the HAdVs,
the E3 region of MAdV-1 is involved in viral patho-
genesis [45,46]. MAdV-1 E3 functions are not directly
comparable to those of HAdVs, however. For exam-
ple, one of the first viral immune evasion strategies
identified for any virus is downregulation of class I
major histocompatibility complex (MHC) antigens on
the surface of infected cells by HAdV-2 [47]. This
function of HAdV E3 gp19K is not mimicked by
MAdV-1 infection [48]. The MAdV-1 E3 proteins do
not have sequence similarity to other known proteins.
Unlike the E4 mRNAs of HAdVs, which are 50 and
30 coterminal, the MAdV-1 E4 mRNAs have different
50 ends but share 30 ends [49]. Predicted proteins have
sequence similarity to HAdV-2 E4orf6 (34K protein)
(MAdV-1 protein originally identified as orf a/b),
E4orf3 protein (MAdV-1 orf a/c), E4orf2, and E4orf6/
7 (MAdV-1 orf d) [34,49]. Little has been reported
about function of the MAdV-1 E4 proteins. However,
when E4orf6 is introduced into human cells by trans-
fection, it coimmunoprecipitates with Cullin 2 (Cul2),
Elongin C, and MAdV-1 E1B 55K protein [50].
Importantly, mouse p53 is degraded when it and
MAdV-1 E4orf6 and E1B 55K protein are coex-
pressed, indicating that E4orf6 (together with E1B
55K) functions as a ubiquitin ligase.
The MLP of MAdV-1 has features like the HAdV-1
MLP, including a TATA box and an inverted CAAT
box, but it lacks a sequence that binds the transcrip-
tion factor USF and it lacks the initiator (INR)
sequence [51]. At late times, the MLP is functional in
MAdV-1-infected cells, as demonstrated by RNAse
protection assays of infected cell RNAs. MAdV-1 late
mRNAs have a typical tripartite leader structure (C.
Coombes, J. Boeke, L. Gralinski, and K. Spindler,
unpublished).
Receptor studies indicate that the mouse coxsackie-
adenovirus receptor (CAR) homolog of the human
CAR used by many HAdVs as the attachment recep-
tor is not used by MAdV-1 [52]. Transfection of
mouse CAR into Chinese hamster ovary cells does not
increase attachment of virus relative to untransfected
cells, and purified HAdV-5 fiber knob does not com-
pete with MAdV-1 binding. MAdV-1 penton base pro-
tein does not have an Arg-Gly-Asp (RGD) sequence
that in HAdVs is important for interaction with entry
receptors. However, the MAdV-1 fiber knob has an
RGD motif in a sequence of the knob that represents
an insertion relative to HAdV-1 fiber sequences [53].
This RGD sequence plays a role in MAdV-1 infection
of cultured fibroblasts. Competition studies indicate
that the fiber knob is the viral attachment protein. Cell
surface heparan sulfate is important for infection, and
av integrin acts as a primary receptor for MAdV-1.
MAdV-1 associates with factor X and factor IX, but
this does not result in increased cellular attachment,
unlike the case for HAdV [54].
MAdV-1 pathogenesis—Tropism,
adaptive immune responses
In contrast to HAdVs, which have an epithelial trop-
ism, MAdV-1 primarily infects endothelial cells and
monocytes/macrophages, and astrocytes can also be
infected [5–8,55,56]. The virus causes a pantropic infec-
tion; high levels of virus found in the central nervous
system (CNS) lead to increased permeability of the
blood–brain barrier, accompanied by altered tight
junction-protein expression and encephalitis [5,6,8,56–
58]. MAdV-1 CNS infection is characterized by viral
brain loads that correlate with disease severity and
induction of matrix metalloproteinase (MMP) activity
[7,59]. Enzyme activity of MMP2 and MMP9, which
are induced in brains during microbial infection or
neurological disease, is increased in mice and cultured
cells upon MAdV-1 infection. This is not accompanied
by increases in MMP mRNA levels, indicating that
the MMP activation is a post-transcriptional event.
MAdV-1 does infect epithelial cells and infects the res-
piratory tract when inoculated intranasally, and
neonatal mice are more susceptible than adults to res-
piratory infection [13,14]. MAdV-1 also causes
myocarditis that is accompanied by myocyte and
endothelial necrosis when inoculated intraperitoneally
or intranasally [10–12]. Many mouse primary cell
types, cell strains, and established cell lines can sup-
port MAdV-1 replication in vitro, including fibroblasts
(3T6, 3T12 and L929) [35,60], endothelial cells
(MBMEC) [57], preadipocyte cells (3T3-L1) [61],
epithelial cells (LA-4, MLE-12 and MLE-15; J.B.
Weinberg, unpublished), cardiac myocytes [12] macro-
phages/monocytes [55], and tumor cells such as lung
adenoma (LA-4), renal adenocarcinoma (RAG) [48],
and rectal carcinoma (CMT-93) cells [62].
Mice infected with MAdV-1 develop adaptive
immune responses, both cell-mediated and humoral.
These responses are important for host survival,
because RAG-1/ mice and SCID mice (deficient in
T cells and B cells) are more susceptible to infection
than wild-type mice [56,63]. Virus-specific cytotoxic
T cells can be detected 4 days postinfection (dpi), peak
at 10 dpi, and then decrease in numbers [64–67]. Stud-
ies with immunodeficient mice have shown that T cells
are required for long-term survival of infection and
contribute to immunopathology during the acute phase
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of infection [68]. CD8 T cells, but not CD4 T cells, are
required for efficient clearance of MAdV-1 from the
lungs and for virus-induced inflammation and weight
loss [69]. These effects of CD8 T cells are not mediated
exclusively by IFN-c, perforin, or Fas/FasL [69,70].
MAdV-1-induced humoral responses have been studied
in outbred and inbred mice. Sublethal infection of out-
bred mice leads to high neutralizing antibody titers
2 weeks after infection that increase for a year before
declining [71]. Infection of inbred mice leads to B cell
proliferation in the spleen 10 dpi, stimulating predomi-
nantly IgG2a antibody [72–74]. Using B-cell-deficient
mice, Moore et al. showed that B cells help prevent
disseminated MAdV-1 infection, and they produce
T-cell-independent antiviral IgM [63]. In studies using
a model in which mice are made immunodeficient by
cyclophosphamide, humoral immunity is important for
protection from MAdV-1 disseminated infection, and




The innate immune response to MAdV-1 infection is
dependent on immune cells and cytokines. Macro-
phages are infected by the virus [5,55]. Peritoneal and
splenic macrophages from infected mice express viral
early and late genes, and peritoneal macrophages pro-
duce infectious virus [5,55]. However, the level of virus
production is low, suggesting that replication is ineffi-
cient or only some cells can produce virus. Bone
marrow-derived macrophages and CD11c+ cells (pre-
dominantly dendritic cells) infected ex vivo express
MAdV-1 mRNAs and proteins [55]. Depletion of
macrophages by clodronate liposome treatment
increases MAdV-1 infection severity [55]. Macrophages
are thus targets and effectors in MAdV-1 infection. In
contrast, depletion of mice of their natural killer (NK)
cells either genetically or biochemically does not alter
MAdV-1 brain viral loads, indicating that in contrast
to other viral infections, NK cells are not required for
control of MAdV-1 infections in the brain [76].
Interferons (IFNs) are major antiviral cytokines.
In vitro, wild-type MAdV-1 infections are resistant to
the effects of type I and type II IFN [77]. In contrast,
E1A mutant infections are sensitive to both types of
IFN, and expression of E1A in the absence of other
viral gene products rescues vesicular stomatitis virus
from the effects of type I IFN. The results indicate
that MAdV-1 uses E1A to inhibit expression of IFN-
stimulated genes. IFNc is not a major antiviral cyto-
kine in MAdV-1 respiratory infection or myocarditis
[12,78]. However, it is necessary for cardiac inflamma-
tion induced by intranasal infection of neonatal mice
[12]. The virus replicates in both neonates and adult
mice, but only neonates develop myocarditis, and there
is higher IFN-c expression in neonates compared to
adults. Thus IFN-c is a proinflammatory mediator in
AdV-induced myocarditis. IFN-c is important for the
induction of the immunoproteasome, an inducible
form of the proteasome involved in protein degrada-
tion and generation of peptides for MHC class I pre-
sentation [79]. Intranasal inoculation of MAdV-1
results in significantly increased immunoproteasome
activity in the lung and heart compared to uninfected
mice [80], and this is dependent on IFNc. The
immunoproteasome is important for survival of neona-
tal mice infected with MAdV-1 [60].
The role of interleukin 1b (IL-1b) in MAdV-1
encephalitis was examined in mice lacking the IL-1
receptor. IL-1b is a proinflammatory cytokine that
contributes to inflammation in the CNS. Surprisingly,
the lack of IL-1 signaling in the mutant mice results in
increased mortality and inflammation during MAdV-1
infection compared to control mice; this is accompa-
nied by an increase in transcription of type I IFN-
stimulated genes [81]. Thus IL-1b, although proinflam-
matory, protects mice from some of the pathogenic
effects of MAdV-1 CNS infections. A similar result is
found in herpes simplex virus 1-induced encephalitis,
in which IL-1b acts synergistically with tumor necrosis
factor alpha [82].
IL-17 is another proinflammatory cytokine; it is pro-
duced by a subset of helper T cells known as Th17
cells. Pulmonary infection of mice by MAdV-1 results
in increased IL-17 mRNA and protein compared to
uninfected mice [83]. IL-17 knockout mice have less
recruitment of neutrophils to the lung than wild-type
mice, but peak viral loads, clearance of virus, and pro-
tective immunity do not differ. This indicates that the
Th17 responses during respiratory infection are not
required for viral control or for pulmonary inflamma-
tion.
Prostaglandin E2 (PGE2) is a lipid mediator that
increases during many viral infections, and it can have
effects on many immune cell types. Production of
PGE2 increases during MAdV-1 respiratory infection,
promoting production of a variety of cytokines [84].
However, mice deficient in PGE2 production do not
differ from wt mice in virus replication, virus-induced
lung inflammation, or protective immunity.
Alpha-defensins are short antimicrobial peptides
with antibacterial activity [85]. These peptides can also
neutralize viruses, and a-defensin binding to HAdV-5
blocks in vitro infection by stabilizing the capsid and
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preventing uncoating of the virion [86–88]. In vivo evi-
dence that defensins are a protective host response for
AdV infection comes from study of MAdV-1 infection
of mice lacking functional enteric a-defensin process-
ing [62]. When mice lacking functional a-defensins in
their small intestine are orally infected with MAdV-1,
there is a dose-dependent increase in susceptibility
compared to wild-type control mice. However, when
the mice are infected intraperitoneally, there is no dif-
ference between mutant and wild-type mice, indicating
that the defensin protective effect is specific to the
small intestine. The effect is not dependent on the host
intestinal microbiota. Viral loads in the defensin-defi-
cient mice are higher in brain, spleen, and ileum only
at late times after infection, suggesting that rather than
directly delaying viral dissemination, a-defensins act
indirectly to protect orally infected mice. Histological
and humoral response assays indicate that the adaptive
immune response to MAdV-1 infection, particularly
the neutralizing antibody response, is delayed in the
absence of functional a-defensins.
A major innate response to virus infection is PKR
activation. PKR is an interferon-stimulated kinase that
is activated by binding to double-stranded RNA pro-
duced in infections by DNA and RNA viruses [89–92].
Activation of PKR leads to phosphorylation of
eukaryotic translation initiation factor eIF2a, which
halts protein synthesis [93,94]. Viruses have evolved a
variety of ways to circumvent this antiviral host
response, including inhibiting PKR phosphorylation,
sequestering PKR, dephosphorylating eIF2a, and
degrading PKR [95]. HAdVs encode VA RNAs that
sequester PKR by binding it as a monomer, preventing
its autophosphorylation/activation [96]. However,
MAdV-1 does not encode a VA RNA [37], and it cir-
cumvents the antiviral PKR response by a mechanism
not previously shown for DNA viruses. MAdV-1
degrades PKR in multiple cell types infected in vitro
[97]. PKR degradation has not been previously
observed for DNA viruses. Inhibiting the proteasome
blocked MAdV-1-induced PKR degradation, indicat-
ing that the degradation likely proceeds by a proteaso-
mal mechanism. The viral gene(s) involved in PKR
degradation have not been identified, but the data
point toward an early viral gene.
MAdV-1 pathogenesis—Persistence
and host genetics of susceptibility
Like HAdVs, MAdV-1 persists in the host after acute
infection [32,33,98]. MAdV-1 is detected in brains,
spleens, and kidneys of outbred mice up to 55 weeks
after intraperitoneal infection [33], and in urine for
up to 2 years [71]. After intranasal inoculation,
MAdV-1 viral genomes can be detected in the hearts
of inbred mice at 9 weeks postinfection [12]. This per-
sistence in the heart can lead to cardiomyocyte hyper-
trophy. It is not known whether MAdV-1 also
persists in lymphocytes, as has been found for
HAdVs [99–101], including in lymphocytes of the gut
lamina propria [102].
Different strains of outbred and inbred mice differ
in their susceptibility to MAdV-1 [6,8,9]. Adult SJL/J
mice are highly susceptible to the virus, whereas other
inbred strains, such as BALB/cJ, are resistant [9]. The
H-2S haplotype of SJL/J mice is not associated with
susceptibility, which was shown to be a quantitative
trait [103]. Genetic mapping using an interstrain back-
cross identified a major quantitative trait locus (QTL)
on mouse chromosome (Chr) 15, Msq1SJL, that
accounts for a significant portion of the total trait
variance between SJL/J and BALB/cJ strains. Fine
mapping localized the QTL to a region of Chr 15 that
encodes genes of the hematopoietic cell surface-ex-
pressed LY6 family [104]. Further mapping was unable
to identify specific Ly6 genes involved in MAdV-1 sus-
ceptibility (Spindler, unpublished), but interestingly,
Ly6E is among other IFN-stimulated genes shown to
enhance the replication of several enveloped viruses,
by targeting a late viral entry step [105,106]. Interval-
specific congenic mice for the Msq1SJL locus were used
to examine the contribution of the locus to disease
phenotypes of intraperitoneally infected mice
[9,58,104]. The locus is responsible for a subset of the
physiological phenotypes that correlate with MAdV-1-
induced encephalitis. Disease phenotype differences
between the congenic mice and parental SJL mice indi-
cate that there are additional host genes involved in
CNS disease in mice.
Mouse adenoviruses type 2 and 3
The genomic sequence of MAdV-2 (HM049560.1) has
been determined and compared to those of MAdV-1
and MAdV-3 (EU835513.1) [18,37,107,108]. Phyloge-
netic analyses showed that the three mouse AdVs have
a close common ancestor, but MAdV-1 and MAdV-3
are closer to each other than to MAdV-2. Strikingly,
although the number of predicted genes is almost the
same, the MAdV-2 genome size of 35 203 bp is con-
siderably larger than the genomes of MAdV -1 and
MAdV-3 (30, 944 and 30 570 bp, respectively). This is
mainly due to larger genes and ORFs in MAdV-2,
although there are also some differences in the number
of ORFs for the early regions E1, E3, and E4. A pecu-
liar feature was noted when analyzing the leader
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sequence of the late mRNA transcripts: in MAdV-1
and -3, as in most AdVs, the leader consists of three
spliced sequences (tripartite sequence), whereas in
MAdV-2, it is a bipartite leader sequence [109]. A
bipartite leader is also found in fowl AdV type 10
[110]. It has been hypothesized that MAdV-2 is a gen-
uine mouse AdV that has continuously coevolved with
M. musculus, whereas MAdV-1 may have switched to
this host from some other species and is still in an
adaption process, including remodeling of the genetic
content [107]. This could also explain the elevated
pathogenicity of MAdV-1 in the house mouse.
The receptors for MAdV-2 and -3 are not known.
Just as in MAdV-1 and -3, no RGD motif is found
in penton base of MAdV-2 [107]. However, the RGD
motif present in the fiber knob of MAdV-1 and -3 is
lacking in the fiber knob of MAdV-2, which has little
sequence identity (10–16%) to AdV fibers of known
structures. A high-resolution crystal structure of the
carboxy-terminus of the MAdV-2 fiber reveals a
domain with the typical AdV fiber head topology and
a domain containing two triple b-spiral repeats of the
shaft domain [111]. The fiber head contains a
monosaccharide N-acetylglucosamine (GlcNAc) bind-
ing site that allows binding to GlcNAc-containing
mucin glycans, potentially representing a target in the
mouse gut. As reported for MAdV-1, mouse CAR
does not serve as receptor for MAdV-2 or -3. Studies
with mouse CAR-transfected B16 melanoma cells did
not reveal increased MAdV-2 or -3 infection (M.
Bieri and S. Hemmi, unpublished). This is consistent
with the fact that few of the residues important for
CAR binding are conserved in the MAdV-2 fiber
head [111]. Competition studies with recombinant
MAdV-2 fiber knob demonstrated that fiber knob is
the attachment protein [111,112], paralleling competi-
tion results for MAdV-1 fiber knob discussed above
[53]. However, the receptors for MAdV-1 and
MAdV-2 on cultured cells are not the same, because
purified MAdV-2 fiber knob does not inhibit MAdV-
1 infection [112].
As discussed above, enteric a-defensins have potent
antiviral effects on in vivo and in vitro MAdV-1 infec-
tion. For enteric MAdV-2, a-defensins have the oppo-
site effect and enhance infection of mouse colon CMT-
93 cells and stem cell-derived small intestinal enteroids
[112]. The enteroid experiments accurately predicted
increased MAdV-2 shedding in the feces of wild-type
mice compared to mice lacking functional a-defensins.
These results are in line with in vitro findings for
human enteric viruses and suggest that some viruses
have evolved to use these host a-defensin proteins to
enhance their replication.
MAdVs as vaccines and vectors
Only a few studies to date have used wild-type or
recombinant MAdVs for therapeutic approaches. This
may be due in part to the relatively fastidious growth
of the viruses and the difficulty in generating recombi-
nant vectors. Robinson et al. engineered an oncolytic
MAdV-1 in which a small deletion in the E1A ren-
dered the protein deficient for binding to pRb, thereby
resembling the human AdVΔ24 vector that has been
shown to replicate selectively in cancer cells defective
for the pRb pathway [113]. This MAdV-1 was engi-
neered to express the immune stimulatory GM-CSF
and tested in immunocompetent syngeneic tumor
models. Compared to the parental vectors, the
MAdV-1 vector with GM-CSF was more effective in
reducing tumor growth in the low immunogenic
Pan02 tumor model and induced a greater systemic
antitumor immune response. This system represents
substantial progress for testing armed oncolytic
viruses, since oncolytic HAdVs cannot productively
infect mouse cells, and effects of immunostimulatory
transgenes on overall virus potency, virus dissemina-
tion, and vector safety cannot be readily assessed in
immunocompromised models, such as nude or SCID
mice.
Genetically modified mouse cells (and possibly
mice) capable of supporting HAdV replication rep-
resent an alternative immunocompetent mouse
model. They would have the advantage that the
vast number of oncolytic HAdV vectors could be
tested directly. Initial studies showed that coinfec-
tion of HAdV-C5 and MAdV-1 or heterologous
overexpression of HAdV-C5 L4-100K can partially
complement late protein expression, which has been
identified as a bottleneck for HAdV-C5 replication
in mouse cells [114]. A second detailed complemen-
tation study used the HAdV-B-derived oncolytic
virus, enadenotucirev (EnAd), in coinfections either
with MAdV-1 or with EnAd viruses containing 24
different MAdV-1 ORFs [113,115]. These transcom-
plementations with MAdV-1 genes failed to rescue
EnAd replication. Thus, the mechanisms preventing
productive replication of HAdVs in mouse cells
seem to vary for the different HAdV species, and
more work needs to be done to understand and
overcome these hurdles.
Oral replication-competent vaccines against HAdV-4
and -7 have long been used to immunize the US mili-
tary against severe respiratory infection caused by
these viruses [116]. MAdV-1 has recently been exam-
ined as a model to study oral replication-competent
AdV vaccines in vivo in a natural host [117].
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Intranasal, intraperitoneal, and natural MAdV-1 infec-
tion generate neutralizing antibodies [1,6,60,63]. Oral
infection of C57BL/6 mice, which have intermediate
susceptibility to MAdV-1 [104], leads to a systemic
infection with moderate bowel pathogenesis and antivi-
ral neutralizing antibody responses [62]. In the MAdV-1
vaccine study, when BALB/c mice, which are more
resistant to MAdV-1 infection [104], were inoculated
orally, there was only a subclinical infection that
also generated a virus-specific neutralizing antibody
response [62,117]. Although clinical signs of disease
were not seen after oral infection of the BALB/c mice,
sporadic shedding of virus in feces occurred, as mea-
sured by qPCR. Importantly, oral immunization with
MAdV-1 protected against homologous virus challenge,
similar to the HAdV-4 and -7 immunizations, with gen-
eration of an adaptive immune response. However, the
oral administration of MAdV-1 alone led to a systemic
infection, even at low doses. Whether this occurs in
humans is not known; the authors note that the HAdV
oral vaccines have been primarily used on a specific
population of young, healthy adults. It would be inter-
esting to test whether the enteric MAdV-2 gives rise to
similar levels of neutralizing antibodies, perhaps in the
absence of systemic spread. The findings of dissemi-
nated infection after MAdV-1 oral infection should
be considered if HAdVs are developed for broader
vaccination.
Conclusions and Perspectives
Mouse adenoviruses are important because they enable
the study of adenoviruses in their natural hosts. Stud-
ies of mouse adenoviruses have revealed tropisms and
pathologies distinct from those seen in HAdV infec-
tions. They have also increased our knowledge of ade-
noviral pathogenesis and revealed new mechanisms of
virus response to the host response in the ‘arms race’
between viruses and cells. While humanized mouse
models [118] and organoid systems [119,120] may
enable study of HAdV pathogenesis, their complexity
and costs may limit their use. Study of mouse AdV
pathogenesis in its natural host, with all the benefits of
mouse genetics and immunological reagents, will con-
tinue to advance our understanding of viral–host inter-
actions.
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